What is Zacks Research’s Estimate for Novartis Q2 Earnings?

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research raised their Q2 2025 EPS estimates for shares of Novartis in a report released on Tuesday, May 13th. Zacks Research analyst E. Bagri now anticipates that the company will earn $2.17 per share for the quarter, up from their prior forecast of $2.14. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.24 EPS, Q4 2025 earnings at $2.07 EPS, FY2025 earnings at $8.76 EPS, Q1 2026 earnings at $2.24 EPS, Q2 2026 earnings at $2.27 EPS, Q3 2026 earnings at $2.23 EPS, FY2026 earnings at $8.93 EPS, Q1 2027 earnings at $2.36 EPS and FY2027 earnings at $9.48 EPS.

Other research analysts also recently issued reports about the company. Barclays reiterated an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. UBS Group reiterated a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Morgan Stanley initiated coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an “underweight” rating for the company. BNP Paribas raised shares of Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Stock Performance

Shares of NVS stock opened at $105.18 on Thursday. The stock’s 50-day moving average price is $109.86 and its 200 day moving average price is $105.81. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $222.18 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 1.70 and a beta of 0.60. Novartis has a 52-week low of $96.06 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The business had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $12.92 billion. During the same period in the prior year, the company earned $1.80 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year.

Institutional Investors Weigh In On Novartis

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Novartis by 35.6% during the fourth quarter. JPMorgan Chase & Co. now owns 423,142 shares of the company’s stock worth $41,176,000 after buying an additional 111,066 shares in the last quarter. Foundations Investment Advisors LLC lifted its position in shares of Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock valued at $8,668,000 after acquiring an additional 18,894 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in shares of Novartis during the 4th quarter worth approximately $239,000. Flywheel Private Wealth LLC purchased a new stake in shares of Novartis during the 4th quarter worth approximately $272,000. Finally, Csenge Advisory Group grew its holdings in shares of Novartis by 63.5% in the 4th quarter. Csenge Advisory Group now owns 16,395 shares of the company’s stock worth $1,595,000 after acquiring an additional 6,369 shares during the period. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio (DPR) is currently 40.47%.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.